This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing

This study has been completed.
Information provided by (Responsible Party):
Stanford University Identifier:
First received: July 6, 2010
Last updated: April 1, 2013
Last verified: April 2013
To implement a new method of performing chest CT imaging in young children at Packard Children's Hospital entitled controlled ventilation infant/young child chest CT scanning. This technique will be used to evaluate early lung disease comparing quantitative chest CT air trapping and airway measurements with lung function measurements in infants, toddlers, and young children with chronic lung disease.

Condition Intervention
Lung Cancer Procedure: Intubation with a cuffed ET Tube Procedure: CT scan Radiation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Quantitative CT air trapping & airway measurements [ Time Frame: 6 mo ]

Secondary Outcome Measures:
  • Functional residual capacity (FRC) & Lung Clearance Index (LCI). [ Time Frame: 6 mo ]
  • Differences between Quantitative CT air trapping & airway measurements & multibreath washout (MBW) FRC and LCI. [ Time Frame: 6 mo ]
  • Correlation between LCI and quantitative air trapping [ Time Frame: 6 mo ]
  • Correlation between bronchial wall thickness measurements/bronchiectasis measurements and LCI/FRC [ Time Frame: 6 mo ]

Enrollment: 30
Study Start Date: January 2009
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   3 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
infants/young children with cystic fibrosis, primary ciliary dyskinesia, or other chronic lung disease, followed at our CF Center or Pulmonary Clinics

Inclusion Criteria:1) Infants and young children (age <= 3 months to < 5 years) and either 2) or 3) below.

2) Respiratory condition (e.g. cystic fibrosis (CF), primary ciliary dyskinesia, bronchopulmonary dysplasia, asthma, or other pulmonary condition) and under the care of a pediatric pulmonologist at LPCH.

3) Oncology condition (e.g. young children with or without cancer, who are being screened for lung metastasis) and are being followed by pediatric oncologists at LPCH.

4) For minors, informed consent by parent or legal guardian.

5) Ability to comply with study visit procedures as judged by the investigator.

Exclusion Criteria:1) Acute wheezing and/or respiratory distress at Study visit.

2) Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset in 1 week preceding Study visit.

3) Oxygen saturation < 90% on room air at study visit.

4) Any medical condition that in the opinion of the investigator precludes subject participation.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01158495

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Terry Earl Robinson Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01158495     History of Changes
Other Study ID Numbers: PEDSVAR0009
SU-07062010-6488 ( Other Identifier: Stanford University )
Study First Received: July 6, 2010
Last Updated: April 1, 2013

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases processed this record on September 21, 2017